So that we can direct you to the most appropriate information about Decapeptyl SR (triptorelin), please choose one of the following options:
*This section of the website is for UK healthcare professionals only and contains promotional content regarding our medicines.
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on 01753 627777
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at http://www.mhra.gov.uk/yellowcard By reporting side effects you can help provide more information on the safety of this medicine.
TRI-UK-005698 Date of preparation: February 2024
Adverse events should be reported. Reporting forms and information can be found at http://www.mhra.gov.uk/yellowcard
Adverse events should also be reported to the Ipsen Medical Information Department on +44(0) 1753 627777 or pharmacovigilance.uk-ie@ipsen.com
A link to the prescribing information can be found in the header.
Decapeptyl® SR (triptorelin) is the only luteinising hormone-releasing hormone agonist (LHRHa) for prostate cancer with a 6-monthly dosage option available in the UK.1–4
Everything you need to help prescribe LHRHa therapy with Decapeptyl® SR. Including licenced indications in prostate cancer, mechanism of action video, and dosing and administration.
Review the results of the peer-reviewed, real-world, retrospective, multicentre Decapeptyl SERvice Evaluation (DESERVE)5 study and see evidence from Decapeptyl® SR clinical studies supporting the efficacy and safety of monthly, 3- monthly, and 6-monthly Decapeptyl.
Download resources to help facilitate the use of less frequent LHRHa injections in your practice.
Information for your patients who may be starting their luteinising hormone-releasing hormone agonist (LHRHa) journey with Decapeptyl® SR or who are considering changing to Decapeptyl® SR.